Literature DB >> 18326523

Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation.

Andreia A Canalli1, Carla F Franco-Penteado, Sara T O Saad, Nicola Conran, Fernando F Costa.   

Abstract

Increased leukocyte adhesion to vascular endothelium contributes to vaso-occlusion in sickle cell disease. Since nitric oxide bioavailability is decreased in sickle cell disease and nitric oxide may inhibit leukocyte adhesion, we investigated whether stimulation of NO-signaling pathways can reduce the adhesive properties of neutrophils from sickle cell disease individuals (sickle cell diseaseneu). sickle cell diseaseneu presented greater adhesion in vitro to both fibronectin and ICAM-1 than control neutrophils. Co-incubation of sickle cell diseaseneu with the nitric oxide-donor agents, sodium nitroprusside and dietheylamine NONOate (DEANO), and the guanylate cyclase stimulator, BAY41-2272, all significantly reduced the increased adhesion to fibronectin/ICAM-1. Oxadiazolo[4,3-a]quinoxalin-1-one, a guanylate cyclase inhibitor, reversed sodium nitroprusside/DEANO-diminished adhesion to fibronectin, implicating cGMP-dependent signaling in this mechanism. Interestingly, intracellular cGMP was significantly higher in neutrophils from sickle cell disease individuals on hydroxyurea (sickle cell diseaseHUneu). Accordingly, sickle cell diseaseHUneu adhesion to fibronectin/ICAM-1 was significantly lower than that of sickle cell diseaseneu. Agents that stimulate the nitric oxide/cGMP-dependent pathway may have beneficial effects on leukocyte function if used in these subjects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18326523     DOI: 10.3324/haematol.12119

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  23 in total

Review 1.  The paradox of the neutrophil's role in tissue injury.

Authors:  George B Segel; Marc W Halterman; Marshall A Lichtman
Journal:  J Leukoc Biol       Date:  2010-11-19       Impact factor: 4.962

Review 2.  Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology.

Authors:  Dachuan Zhang; Chunliang Xu; Deepa Manwani; Paul S Frenette
Journal:  Blood       Date:  2016-01-12       Impact factor: 22.113

Review 3.  cGMP modulation therapeutics for sickle cell disease.

Authors:  Nicola Conran; Lidiane Torres
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-28

4.  Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial.

Authors:  Carolyn Hoppe; Eufemia Jacob; Lori Styles; Frans Kuypers; Sandra Larkin; Elliott Vichinsky
Journal:  Br J Haematol       Date:  2017-03-28       Impact factor: 6.998

5.  Study of correlation of nitrite levels with malonaldehyde and the prognosis of patients with sickle cell disease on hydroxyurea, Ceará-Brazil.

Authors:  Romélia Pinheiro Gonçalves; Darcielle Bruna Dias Elias; Hemerson Iury Ferreira Magalhães; Jacqueline Holanda de Souza
Journal:  J Clin Lab Anal       Date:  2011       Impact factor: 2.352

Review 6.  Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.

Authors:  Johannes-Peter Stasch; Pál Pacher; Oleg V Evgenov
Journal:  Circulation       Date:  2011-05-24       Impact factor: 29.690

7.  Participation of Mac-1, LFA-1 and VLA-4 integrins in the in vitro adhesion of sickle cell disease neutrophils to endothelial layers, and reversal of adhesion by simvastatin.

Authors:  Andreia A Canalli; Renata F Proença; Carla F Franco-Penteado; Fabiola Traina; Tatiana M Sakamoto; Sara T O Saad; Nicola Conran; Fernando F Costa
Journal:  Haematologica       Date:  2010-12-20       Impact factor: 9.941

8.  Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions.

Authors:  Gregory J Kato; Robert P Hebbel; Martin H Steinberg; Mark T Gladwin
Journal:  Am J Hematol       Date:  2009-09       Impact factor: 10.047

Review 9.  Pathophysiology and recent therapeutic insights of sickle cell disease.

Authors:  Firdosh Shah; Mitesh Dwivedi
Journal:  Ann Hematol       Date:  2020-03-10       Impact factor: 3.673

10.  Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice.

Authors:  Camila Bononi Almeida; Christoph Scheiermann; Jung-Eun Jang; Colette Prophete; Fernando Ferreira Costa; Nicola Conran; Paul S Frenette
Journal:  Blood       Date:  2012-07-25       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.